US Irritable Bowel Syndrome Treatment Market to 2027 - Country Analysis and Forecasts by Type (IBS with Diarrhea (IBS-D), IBS with Constipation (IBS-C), Mixed IBS (IBS-M)); Product (Rifaximin, Eluxadoline, Lubiprostone, Linaclotide, Others); Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Pharmacies)
The US irritable bowel syndrome treatment market is expected to reach US$ 1,276.21 Mn in 2027 from US$ 586.61 Mn in 2019. The market is estimated to grow with a CAGR of 10.3% from 2020-2027.
The growth of the market is driven by the factors such as, increasing prevalence of irritable bowel syndrome and associated conditions, and increasing numbers of FDA approvals & drug developments. On the other hand, limited number of product availability and treatment inefficiency is likely to restraint the growth of market during the forecast years.
Irritable Bowel Syndrome treatment market is a majorly observed chronic gastrointestinal condition that is caused due to disturbances in bowel habits and abdominal pain. The disease is also known as spastic colon, irritable colon, mucous colitis, and spastic colitis. Irritable bowel syndrome shows symptoms such as abdominal pain, constipation, diarrhea, and cramping.
Health systems across the regions are witnessing considerable growth in the incidence of irritable bowel syndrome. According to data published by International Foundation for Gastrointestinal Disorders, among all irritable bowel syndrome patients about 40% of people have mild IBS, around 35% have moderate IBS, and an estimated have 25% severe IBS. Many people don't recognize IBS symptoms. Certain factors such as food allergies, developing stages of gastroenteritis, sporadic movements of colon, abnormal composition of serotonin in colon, and mild celiac disease are some of the risk factors which are causing irritable bowel syndrome. These factors are projected to accelerate the rate of prevalence of irritable bowel syndrome across the globe. For instance, according to a study published on NCBI in 2018, irritable bowel syndrome is estimated to affect around 10% to 16% of the US population each year. Such staggering prevalence of irritable bowel syndrome is likely to boost the US irritable bowel syndrome treatment market during the forecast period.
In order to cope up against irritable bowel syndrome in the country, the companies involved in the drug development for irritable bowel syndrome are taking constructive steps to implement awareness programs with an aim to spread awareness amongst the populations. For instance, in 2018, the collaboration of Allergan PLC and Ironwood launched an Interactive Digital Destination platform to encourage sufferers to get educated and take action. Such initiatives are also anticipated to drive the demand for irritable bowel syndrome treatment market in US.
US Irritable Bowel Syndrome Treatment Market Revenue and Forecast to 2027 (US$ Mn)
Get more information on this report :
US Irritable Bowel Syndrome Treatment - Market Segmentation
US Irritable Bowel Syndrome Treatment Market - By Type
- IBS with Diarrhea (IBS-D)
- IBS with Constipation (IBS-C)
- Mixed IBS (IBS-M)
US Irritable Bowel Syndrome Treatment Market - By Product
- Rifaximin
- Eluxadoline
- Linaclotide
- Lubiprostone
- Others
US Irritable Bowel Syndrome Treatment Market - By Distribution Channel
- Hospitals Pharmacies
- Drug Stores and Retail Pharmacies
- Online Pharmacies
Company Profiles
- Ironwood Pharmaceuticals, Inc.
- Allergan Plc.
- Sebela Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Limited
- Alfasigma S.p.A.
- Astellas Pharma Inc.
- AstraZeneca
- Synthetic Biologics, Inc.
- Bausch + Lomb Incorporated
- Lannett Company Inc.
1. Introduction
1.1 Study Scope
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 US Irritable Bowel Syndrome Treatment Market – ByType
1.3.2 US Irritable Bowel Syndrome Treatment Market – By Product
1.3.3 US Irritable Bowel Syndrome Treatment Market – By Distribution Channel
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. US Irritable Bowel Syndrome Treatment Market Landscape
4.1 Market Overview
4.2 PEST Analysis
4.2.1 US: PEST Analysis
4.3 Expert Opinion
5. US Irritable Bowel Syndrome Treatment Market – Key Market Dynamics
5.1 Key Drivers
5.1.1 Increasing prevalence of irritable bowel syndrome and associated conditions
5.1.2 Increasing number of FDA approvals and drug developments
5.2 Key Market Restraints
5.2.1 Limited number of product availability and treatment inefficiency
5.2.2 Disruptive effect of corona virus on the US economy
5.3 Key Market Opportunities
5.3.1 Increasing disposable incomes of the population
5.4 Future Trends
5.4.1 Development of medical devices for the treatment of irritable bowel syndrome
5.5 Impact Analysis
6. Irritable Bowel Syndrome Treatment – US Market Analysis
6.1 US Irritable Bowel Syndrome Treatment Market Overview
6.2 Market Positioning of Key Players
7. US Irritable Bowel Syndrome Treatment Market Analysis – By Type
7.1 Overview
7.2 Global Irritable Bowel Syndrome Treatment Market Share by Type 2019 & 2027 (%)
7.3 Mixed IBS (IBS-M)
7.3.1 Overview
7.3.2 Mixed IBS (IBS-M) Market Revenue and Forecast to 2027 (US$ Mn)
7.4 IBS with Diarrhea (IBS-D)
7.4.1.1 IBS with Diarrhea Market Revenue and Forecast to 2027 (US$ Mn)
7.5 IBS with Constipation (IBS-C)
7.5.1.1 IBS with Constipation (IBS-C) Market Revenue and Forecast to 2027 (US$ Mn)
8. US Irritable Bowel Syndrome Treatment Market Analysis And Forecasts To 2027–Product
8.1 Overview
8.2 Global Irritable Bowel Syndrome Treatment Market Share by Product 2019 & 2027 (%)
8.3 Rifaximin
8.3.1 Overview
8.3.2 Rifaximin Market Revenue and Forecast to 2027 (US$ Mn)
8.4 Eluxadoline
8.4.1 Overview
8.4.2 Eluxadoline Market Revenue and Forecast to 2027 (US$ Mn)
8.5 Lubiprostone
8.5.1 Overview
8.5.2 Lubiprostone Market Revenue and Forecast to 2027 (US$ Mn)
8.6 Linaclotide
8.6.1 Overview
8.6.2 Linaclotide Market Revenue and Forecast to 2027 (US$ Mn)
8.7 Others
8.7.1 Overview
8.7.2 Others Market Revenue and Forecast to 2027 (US$ Mn)
9. US Irritable Bowel Syndrome Treatment Market Analysis And Forecasts To 2027 – Distribution Channel
9.1 Overview
9.2 Global Irritable Bowel Syndrome Treatment Market Share by Distribution Channel 2019 & 2027 (%)
9.3 Hospitals Pharmacies
9.3.1 Overview
9.3.2 Hospitals Pharmacies Market Revenue and Forecast to 2027 (US$ Mn)
9.4 Drug Stores and Retail Pharmacies
9.4.1 Overview
9.4.2 Drug Stores and Retail Pharmacies Market Revenue and Forecast to 2027 (US$ Mn)
9.5 Online Pharmacies
9.5.1 Overview
9.5.2 Online Pharmacies Market Revenue and Forecast to 2027 (US$ Mn)
10. US Irritable Bowel Syndrome Treatment Market –Industry Landscape
10.1 Overview
10.2 Growth Strategies In The Irritability Bowel Syndrome Treatment Market, 2017-2019
10.3 Organic Growth Strategies
10.3.1 Overview
10.3.2 Recent Organic Developments By Players In The Irritability Bowel Syndrome Treatment Market
10.4 Inorganic Growth Strategies
10.4.1 Overview
10.4.2 Recent Inorganic Developments By Players In The Irritability Bowel Syndrome Treatment Market
11. Company Profiles
11.1 Ironwood Pharmaceuticals, Inc.
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Allergan Plc.
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Sebela Pharmaceuticals, Inc.
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Takeda Pharmaceutical Company Limited
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Alfasigma S.p.A.
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Astellas Pharma Inc.
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 AstraZeneca
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Synthetic Biologics, Inc.
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 SWOT Analysis
11.8.5 Key Developments
11.9 Bausch Health Companies Inc.
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
11.10 Lannett Company Inc.
11.10.1 Key Facts
11.10.2 Business Description
11.10.3 Products and Services
11.10.4 Financial Overview
11.10.5 SWOT Analysis
11.10.6 Key Developments
12. Appendix
12.1 About The Insight Partners
12.2 Word Index
LIST OF TABLES
Table 1. US: Irritable Bowel Syndrome Treatment Market Revenue Share, by Type (US$ Mn)
Table 2. US: Irritable Bowel Syndrome Treatment Market Revenue Share, by Product (US$ Mn)
Table 3. US: Irritable Bowel Syndrome Treatment Market Revenue Share, by Distribution Channel (US$ Mn)
Table 4. Recent Organic Developments In The Irritability Bowel Syndrome Treatment Market
Table 5. Recent Inorganic Developments In The Irritability Bowel Syndrome Treatment Market
Table 6. List of Abbreviation
LIST OF FIGURES
Figure 1. US Irritable Bowel Syndrome Treatment Market Segmentation
Figure 2. US Irritable Bowel Syndrome Treatment Market Overview
Figure 3. Mixed IBS (IBS–M) is Expected to Show Remarkable Growth During Forecast Period
Figure 4. Linaclotide is Expected to Have Fastest Growth During Forecast Period
Figure 5. US Irritable Syndrome Treatment Market, Industry Landscape
Figure 6. US: PEST Analysis
Figure 7. Expert Opinion
Figure 8. Overview of US Irritable Bowel Syndrome Treatment Market
Figure 9. Market Positioning Of Key Players In US Irritable Bowel Syndrome Treatment Market
Figure 10. Global Irritable Bowel Syndrome Treatment Market Share by Type 2019 & 2027 (%)
Figure 11. Mixed IBS (IBS-M) Market Revenue And Forecasts To 2027 (US$ Mn)
Figure 12. IBS with Diarrhea Market Revenue And Forecasts To 2027 (US$ Mn)
Figure 13. IBS with Constipation (IBS-C) Market Revenue And Forecasts To 2027 (US$ Mn)
Figure 14. Global Irritable Bowel Syndrome Treatment Market Share by Product 2019 & 2027 (%)
Figure 15. Rifaximin Market Revenue And Forecasts To 2027 (US$ Mn)
Figure 16. Eluxadoline Market Revenue And Forecasts To 2027 (US$ Mn)
Figure 17. Lubiprostone Market Revenue And Forecasts To 2027 (US$ Mn)
Figure 18. Linaclotide Market Revenue And Forecasts To 2027 (US$ Mn)
Figure 19. Others Market Revenue And Forecasts To 2027 (US$ Mn)
Figure 20. Global Irritable Bowel Syndrome Treatment Market Share by Distribution Channel 2019 & 2027 (%)
Figure 21. Hospitals Pharmacies Market Revenue And Forecasts To 2027 (US$ Mn)
Figure 22. Drug Stores and Retail Pharmacies Market Revenue And Forecasts To 2027 (US$ Mn)
Figure 23. Online Pharmacies Market Revenue And Forecasts To 2027 (US$ Mn)
Figure 24. Growth Strategies in the Irritability Bowel Syndrome Treatment Market, 2017-2019
The List of Companies - US Irritable Bowel Syndrome Treatment Market
- Ironwood Pharmaceuticals, Inc.
- Allergan Plc.
- Sebela Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Limited
- Alfasigma S.p.A.
- Astellas Pharma Inc.
- AstraZeneca
- Synthetic Biologics, Inc.
- Bausch + Lomb Incorporated
- Lannett Company Inc.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the US Irritable Bowel Syndrome Treatment market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the global hemostats market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth regional market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution